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Plasma cells (PCs) are terminally differentiated B-cells produc-
ing large amounts of immunoglobulins (Igs). In humans, most
circulating Igs are produced by bone marrow PCs. PCs differen-
tiate from naïve or memory B-cells usually activated by specific
antigens. It is still controversial whether the regulation of PC
numbers and the “active” in vivo Ig diversity depend or not on
non-specific reactivation of B-cells during infections. Depending
on the stimulus (T-independent/T-dependent antigen, cytokines,
and partner cells) and B-cell types (naïve or memory, circulating
or germinal center, lymph nodes or spleen, and B1 or B2), both the
phenotype and isotype of PCs differ suggesting that PC diversity
is either linked to B-cell diversity or to the type of stimulus or
to both. Knowledge of the mechanisms supporting PC diversity
has important consequences for the management of: (i) plasma-
cell neoplasias such as Multiple Myeloma and Waldenström’s
Macroglobulinemia, (ii) vaccine protection against pathogens, and
(iii) auto-immune diseases.
In this E-book, Drs. Xu and Banchereau review current knowl-
edge on the molecules involved in PC generation induced by either
dendritic cells or macrophages in T-dependent or T-independent
B-cell activation (1). They further show how dendritic cells or
macrophages provide a second signal (membrane-bound or sol-
uble factors) that is required for PC generation. As proposed by
the authors, increasing the crosstalk between Ag presenting cells
and B-cells may lead to enhanced vaccine-induced Ab responses.
On the contrary, interruption of this crosstalk might represent
new strategies to treat auto-immune diseases. As splenectomy
is the standard of care of patients with auto-immune thrombo-
cytopenia, Dr. Mahévas and collaborators took the opportunity
to characterize splenic PCs (2). They show that in patients who
did not receive rituximab, spleen PCs had a plasmablast signa-
ture. By contrast, spleen PCs from patients who received ritux-
imab had a plasma-cell signature. These in vivo findings suggest
that short-lived immature PCs differentiated into long-lived PCs
in situ, raising the question of the existence of splenic niches
for long-lived PCs. In the spleens of naïve mice, Dr. Holodick
and collaborators assess the origin and function of the small
CD138+ B1a cell population. They show that this population is
likely responsible for a substantial portion of natural IgM that
differs from IgM produced by other B1a cell subsets, underlying
the heterogeneity of IgM-secreting cells within B1a cells (3). Dr.
Cunningham and collaborators review current knowledge on B1b
cells in humans and mice, and discuss how B1 and B2 cells might
interplay during the antibody response to proteins like porins from
pathogenic microbes, which induce both classical T-dependent
and T-independent response (4).
Long-lived PCs are usually found within bone marrow niches,
the composition of which is still a matter of debate. Although
bone marrow niches are known to provide favorable environ-
ments for PC survival, Dr. Tooze explores how a self-renewal
model could account for the maintenance of long-lived PCs within
niches (5). Indeed, Dr. Tooze describes how regular re-entry into
cell cycle could account for PC maintenance. Independently of
possible self-renewal, long-life of PCs involves several mecha-
nisms such as autophagy. Indeed, as professional secretory cells
dedicated for massive synthesis, assembly, and secretion of Abs,
PCs display high ER stress (6). Using mice knocked-out for atg5,
Drs. Oliva and Cenci show that both generation and long-life
of PCs was decreased in the absence of autophagy, highlight-
ing the role of protein catabolism (6). Generation of long-lived
PCs requires cytokines and growth factors. Dr. Moens and col-
laborators provide an overview of in vitro studies (mouse and
human origin) that evaluated the role of the different cytokines
in inducing differentiation of distinct B cell subsets into PCs.
They underline the central role of IL21 in PC generation from
naïve B-cells (7). IL21, as other cytokines and growth factors,
modulates the expression of Bcl2 molecules, and in that way the
survival/death threshold of PCs (7). In myeloma cells, the expres-
sion of the pro (BH3-only, Bax, Bak) and anti-apoptotic (Bcl2,
Mcl1) molecules of the Bcl2 family is different according to the
molecular classification of patients with multiple myeloma, as
shown by Drs. Gomez-Bougie and Amiot, who conclude that the
apoptosis threshold in myeloma differs greatly between subsets of
patients (8). Myeloma cells also display a wide heterogeneity with
regard to phenotype. Dr. Robillard and collaborators describe the
diversity of myeloma immunophenotypes, which is useful for the
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evaluation of minimum residual disease after treatment and rep-
resents a source of targets for antibody-based therapy in subsets
of patients (9).
The nine contributions in this topic describe the heterogeneity
of PCs and discuss mechanisms involved in heterogeneity. Alto-
gether, these contributions provide an overview on mechanisms
involved in PC cell diversity in the context of normal and
pathologic Ab responses.
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